Nikkei Rallies as BOJ Governor Ueda Signals Continued Monetary Support

MT NewswiresDec 26 14:50

Shionogi to Acquire Ping An Insurance's Stakes in JVs

MT NewswiresDec 26 09:36

Fanpeep --- Submission of the clinical trial plan for the additional Phase III clinical trial of the functional peptide "SR-0379."

Fanpep <4881> announced on the 9th that it submitted a clinical trial plan for an additional Phase 3 clinical trial (SR0379-JP-SU-02 trial, hereinafter referred to as the 02 trial) for the functional peptide "SR-0379," which is being developed for the treatment of skin ulcers, to the Pharmaceuticals and Medical Devices Agency (hereinafter referred to as PMDA) on December 6, aiming for early approval. The 02 trial is expected to start following PMDA's designated investigation.

Fisco JapanDec 11 14:29

Digest of stocks in emerging markets: INGS continues to rise significantly, and R Planner surges.

＜245A＞ INGS 2575 +114 significantly continued to rise. After the market closed yesterday, the fast report on direct store revenue for the period ending in August 2025 was released. Same-store sales for the ramen business increased by 7.8% year-on-year, and the restaurant business increased by 9.7%, continuing to show an increasing revenue trend. As of the end of November 2024, there are 32 direct stores in the ramen business (an increase of 4 stores) and 32 stores in the restaurant business (an increase of 4 stores). In November, the same-store results for the ramen business continued.

Fisco JapanDec 10 15:19

Stem Inc --- continued growth, patent registration in Europe for the treatment of cardiomyopathy using the regenerative medicine Redasemtide, etc.

Continuation of increase. After the trade yesterday, it was announced that a patent for a new treatment for cardiomyopathy and associated chronic heart failure using ledasemtide (a peptide drug derived from HMGB1) already licensed to Shionogi & Co., Ltd. <4507> has been registered in Europe. This patent aims to expand the range of applications for ledasemtide. With the establishment of the patent, ledasemtide can be used in the European region for treating cardiomyopathy and the chronic heart failure resulting from it.

Fisco JapanDec 10 09:15

Idemitsu Kosan, Sumitomo Osaka Cement, etc. (additional) Rating.

Upgraded - bullish code stock name brokerage firm previous change after----------------------------------------------------------<9468>KADOKAWA Macquarie "Neutral" "Outperform" <5233> Taiheiyo Cement Daiwa "2" "1" target stock price change code stock name brokerage firm previous change after----------------------------------------------

Fisco JapanNov 21 11:29